These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8281873)

  • 21. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
    Batts KP; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial quantitative liver function tests in patients with primary biliary cirrhosis: a prospective long-term study.
    v Schönfeld J; Breuer N; Zotz RB; Beste M; Goebell H
    Digestion; 1997; 58(4):396-401. PubMed ID: 9324169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial determination of type III procollagen amino propeptide serum levels in patients with histologically progressive and non-progressive primary biliary cirrhosis.
    Beukers R; van Zanten RA; Schalm SW
    J Hepatol; 1992 Jan; 14(1):22-9. PubMed ID: 1737913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
    Simko V; Michael S; Prego V
    Am J Gastroenterol; 1994 Mar; 89(3):392-8. PubMed ID: 8122652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
    Avezov SA; Mansurov FKh
    Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
    Corpechot C; Chazouillères O; Poupon R
    J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.
    Guo GY; Shi YQ; Wang L; Ren X; Han ZY; Guo CC; Cui LN; Wang JB; Zhu J; Wang N; Zhang J; Cai Y; Han Y; Zhou XM; Fan DM
    Aliment Pharmacol Ther; 2015 Jul; 42(2):221-30. PubMed ID: 25982180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical observation on the safety and efficacy of ursodeoxycholic acid and fuzheng huayu capsule in the treatment of primary biliary cirrhosis].
    Wu Y; Yao DK; Zhu L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Nov; 32(11):1477-82. PubMed ID: 23359968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years.
    Chang ML; Chen WT; Chan TM; Lin CY; Chang MY; Chen SC; Chien RN
    Front Immunol; 2022; 13():869018. PubMed ID: 35663951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.
    Batta AK; Salen G; Arora R; Shefer S; Tint GS; Abroon J; Eskreis D; Katz S
    Hepatology; 1989 Oct; 10(4):414-9. PubMed ID: 2777202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y; Doy M; Tanaka N; Shoda J; Osuga T; Nakano M; Aikawa T
    J Clin Gastroenterol; 1994 Jan; 18(1):36-41. PubMed ID: 8113583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
    Lens S; Leoz M; Nazal L; Bruguera M; Parés A
    Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A two-year follow-up study on the efficacy of ursodeoxycholic acid on primary biliary cirrhosis in different stages].
    Zhu JY; Li ZS; Yan W; Wang JH; Zhou XM; Wang RA; Huang XF; Shi YQ; Dong XY; Han ZY; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2010 Oct; 18(10):735-9. PubMed ID: 21059288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
    Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
    Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study.
    Rolandi E; Franceschini R; Cataldi A; Cicchetti V; Carati L; Barreca T
    Eur J Clin Pharmacol; 1991; 40(5):473-6. PubMed ID: 1679391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue.
    Poupon RE; Balkau B; Guéchot J; Heintzmann F
    Hepatology; 1994 Mar; 19(3):635-40. PubMed ID: 8119688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
    Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
    Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.